Ophthalmology Innovation Summit
Ophthalmology Innovation Summit
November 16, 2017
2 min watch
Save

VIDEO: Luxturna looks to be first gene therapy for retinal disease in US

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW ORLEANS ― At the Ophthalmology Innovation Summit here, Paulo Falabella, MD, medical affairs ophthalmic lead at Spark Therapeutics, discusses the company’s progress with getting Luxturna gene therapy approved for use in the U.S.